Radiopharmaceutical hopeful Draximage is laying the groundwork for its entry into the nuclear medicine market. The Montreal company this month signed an agreement with a biotechnology firm that should enable Draximage to expand its R&D pipeline. It
Radiopharmaceutical hopeful Draximage is laying the groundwork for its entry into the nuclear medicine market. The Montreal company this month signed an agreement with a biotechnology firm that should enable Draximage to expand its R&D pipeline. It also closed the acquisition of a pharmaceutical manufacturing facility in Quebec that will become its permanent headquarters.
In the first agreement, Draximage signed a deal with Molecular Targeting Technology (MTTI) of Malvern, PA, to develop, manufacture, and market new imaging agents. The first potential product covered by the relationship is Amiscan, a formulation of technetium-99m glucarate being developed for the early diagnosis of acute myocardial infarction. Preliminary results with the agent indicate that it could be used to diagnose and localize myocardial infarct within a few hours of onset.
In the other deal, Draximage's parent company, Draxis Health, completed the acquisition from IVX BioScience of a manufacturing facility in Kirkland, Quebec, that formerly was used by pharmaceutical giant Burroughs Wellcome. The facility will become the headquarters for Draximage and will assume manufacturing responsibilities for other Draxis products. Draximage is developing a range of peptide-based targeted radiopharmaceuticals for applications such as deep vein thrombosis, oncology, and lung and kidney scans (SCAN 2/18/98).
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.